Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBM6-AD is an allogeneic tumor lysate vaccine derived from a specific glioblastoma stem cell line (GBM6). It is designed to stimulate a multi-antigenic immune response against glioma-associated antigens. The vaccine is typically administered with adjuvants such as poly-ICLC or imiquimod, or loaded into autologous dendritic cells to enhance immunogenicity. Clinical studies have evaluated its safety and ability to induce tumor-infiltrating CD8+ T-cell responses in patients with low-grade gliomas, recurrent high-grade gliomas, and diffuse midline gliomas. By presenting a broad spectrum of tumor-specific antigens, GBM6-AD aims to overcome the genetic elusiveness and infiltrative nature of malignant brain tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GBM6-AD.